Ligand Pharmaceuticals Incorporated (LGND) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Ligand Pharmaceuticals Incorporated  (NASDAQ: LGND)


Ligand Pharmaceuticals Incorporated's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Ligand Pharmaceuticals Incorporated's ROI in the second quarter of 2026?
Ligand Pharmaceuticals Incorporated achieved a return on average invested assets (ROI) of 11.95 % in its second quarter of 2026, which is below Ligand Pharmaceuticals Incorporated's average return on investment, which stands at 12.2%.

ROI has improved compared to 11.49% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 71 other companies had a higher return on investment. While the total ranking for ROI remained the same, compared to the first quarter of 2026 at no. 702.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 85.11 % 51.44 % 31.34 % 18.17 % 8.79 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 2,139 1,491 1,523 1,446 884
Return On Investment (TTM) 11.95 % 11.49 % 10.59 % 4.76 % -8.51 %
LGND's Overall Ranking # 702 # 702 # 611 # 1186 # 2453
Seq. Investment Change TTM 23.49 % 13.72 % 15.15 % 14.48 % 1.02 %
Seq. Net Income Change TTM 28.43 % 23.39 % 156.18 % - -
Net Income (TTM) in Millions 197 154 124 49 -76

LGND Company Profile >> Back to LGND Roi Comparisons >> See Annual LGND Return On Investment



Return On Investment LGND's Ranking
Within: No.
Industry # 27
Sector # 72
Overall # 702

Return On Investment Statistics
High Average Low
80.42 %
12.2 %
-14.97 %
(Sep 30 2015)   (Mar 31 2025)







Financial Statements
Ligand Pharmaceuticals Incorporated's II. Quarter Investments $ 2,139 Millions LGND's Balance sheet
Ligand Pharmaceuticals Incorporated's II. Quarter Income $ 49 Millions Quarterly LGND's Income Statement
LGND's Income by Division See LGND's Income by Division


LGND Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 1,523 905 780 664 1,256
Y / Y Investment Growth 68.37 % 16.01 % 17.47 % -47.14 % -0.5 %
Net Income in Millions 124 -4 52 -33 57
Y / Y Net Income Growth - - - - -
Annual Return On Investment 8.17 % -0.45 % 6.69 % -5.03 % 4.55 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 8.17 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
LGND's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for LGND's Competitors
Subscribers only: Roi for Ligand Pharmaceuticals Incorporated's Suppliers
Subscribers only: Return On Investment for LGND's Customers

Other Ratios
LGND's Roa LGND's Inventory Turnover Ratio LGND's Growth Rates LGND's Dividend Statistics
LGND's Profitability Ratios LGND's Asset Turnover Ratio LGND's Dividend Growth
LGND's Roe LGND's Valuation Ratios LGND's Financial Strength Ratios LGND's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %
Agilent Technologies inc   19.84 %
Illumina Inc   19.61 %
Puma Biotechnology Inc   19.60 %
United Therapeutics Corporation  19.53 %
Zoetis Inc   19.44 %
Krystal Biotech Inc   19.16 %
Carlisle Companies Incorporated  18.88 %
Neurocrine Biosciences Inc   17.51 %
Intuitive Surgical Inc   17.11 %
Theravance Biopharma inc   17.10 %
Standard Biotools Inc   16.38 %
Inspire Medical Systems inc   16.34 %

Date modified: 2026-09-26T07:17:25+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.